Further to its announcement of 16 April 2025, Benchmark Holdings plc
("Benchmark", the "Group" or the "Company") is pleased to announce its proposals
for the return of the vast majority of the net proceeds from the completion of
its disposal of the Genetics Business to Shareholders, the proposed cancellation
of the admission to trading of its Ordinary Shares on (i) AIM, a market operated
by the London Stock Exchange, and (ii) Euronext Growth Oslo (the "De-Listings"),
and the proposed re-registration of the Company as a private limited company,
together the "Proposals".
The Proposals are subject to Shareholder approval at a General Meeting and to
the approval of the cancellation to trading of the Company's Ordinary Shares on
Euronext Growth Oslo by the Euronext Oslo (the "Norwegian Approval"). A circular
containing full details of the Proposals and expected timetable of principal
events (the "Circular"), together with certain accompanying documents, has been
published on the Company's website at
https://www.benchmarkplc.com/investors/delisting and will also be sent to
shareholders shortly. Unless otherwise defined, capitalised terms used in this
announcement have the same meanings as ascribed to them in the Circular.
Introduction
Following the disposal of the Group's Genetics Business, which completed on 31
March 2025, the Company has been assessing how best to return excess capital to
shareholders and position the remaining operating businesses for future growth.
Accordingly, the Company today announces a series of inter-conditional
proposals, namely its intention to:
o cancel the admissions to trading of the Company's Ordinary Shares on AIM and
Euronext Growth Oslo